Clinical and bacteriological survey of diabetic foot infections in Lisbon

Diabetes Research and Clinical Practice

Volumn 95, Issue 1, 2012, Pages 153-161

  Mendes, J J ^a   Marques Costa, A ^b   Vilela, C ^c   Neves, J ^d   Candeias, N ^e   Cavaco Silva, P ^f   Melo Cristino, J ^g  

^a HOSPITAL DE SANTA MARTA   (Portugal)

^b Podiatry Outpatient Clinic   (Portugal)

^c FACULDADE DE MEDICINA VETERINÁRIA   (Portugal)

^d HOSPITAL DE SANTO ANTÓNIO DOS CAPUCHOS   (Portugal)

^e HOSPITAL CURRY CABRAL   (Portugal)

^f INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE EGAS MONIZ   (Portugal)

^g INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Diabetic foot; Epidemiology; Infection; Microbiology; Portugal

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAMIDE DERIVATIVE;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ASPIRATION; BACTERIUM CULTURE; BACTERIUM ISOLATE; BIOPSY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DIABETIC FOOT; DISEASE DURATION; DRUG CONTRAINDICATION; FEMALE; FOOT ULCER; HEALTH SURVEY; HUMAN; HUMAN TISSUE; INFORMATION PROCESSING; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGICAL PARAMETERS; MULTIDRUG RESISTANCE; OBSERVATIONAL STUDY; PORTUGAL; SMEAR; STAPHYLOCOCCUS; STRUCTURED QUESTIONNAIRE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DIABETIC FOOT; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; PORTUGAL; PREVALENCE; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84355162932     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.10.001     Document Type: Article

References (32)

1. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87(1):4-14.
2. Richard J.L., Sotto A., Lavigne J.P. New insights in diabetic foot infection. World J Diabetes 2011, 2(2):24-32.
3. Citron D.M., Goldstein E.J., Merriam C.V., Lipsky B.A., Abramson M.A. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 2007, 45(9):2819-2828.
4. Tascini C., Piaggesi A., Tagliaferri E., Iacopi E., Fondelli S., Tedeschi A., et al. Microbiology at first visit of moderate-to-severe diabetic foot infection with antimicrobial activity and a survey of quinolone monotherapy. Diabetes Res Clin Pract 2011.
5. Karchmer A.W., Gibbons G.W. Foot infections in diabetes: evaluation and management. Curr Clin Top Infect Dis 1994, 14:1-22.
6. National Institute for Health and Clinical Excellence NICE clinical guideline 119: inpatient management of diabetic foot problems 2011, National Institute for Health and Clinical Excellence, London.
7. Joseph W.S., Lipsky B.A. Medical therapy of diabetic foot infections. J Am Podiatr Med Assoc 2010, 100(5):395-400.
8. Organization for economic co-operation and development (OECD). Health at a glance 2009: OECD indicators; 2009. Available from: [last update September 2009, last accessed June 2011]. http://www.oecd.org/dataoecd/32/34/43541373.pdf.
9. Moet G.J., Jones R.N., Biedenbach D.J., Stilwell M.G., Fritsche T.R. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007, 57(1):7-13.
10. Schaper N.C. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev 2004, 20(Suppl. 1):S90-S95.
11. Executive summary: standards of medical care in diabetes-2009. Diabetes Care 2009, 32(Suppl. 1):S6-S12.
12. Lavery L.A., Armstrong D.G., Peters E.J., Lipsky B.A. Probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?. Diabetes Care 2007, 30(2):270-274.
13. Alavi A., Niakosari F., Sibbald R.G. When and how to perform a biopsy on a chronic wound. Adv Skin Wound Care 2010, 23(3):132-140. quiz 141-2.
14. Bonham P.A. Swab cultures for diagnosing wound infections: a literature review and clinical guideline. J Wound Ostomy Continence Nurs 2009, 36(4):389-395.
15. Murray P.R., Baron E.J., Jorgensen J.H., Pfaller M.A., Yolken R.H. Manual of clinical microbiology 2003, ASM Press, Washington, DC.
16. Woo P.C., Leung A.S., Leung K.W., Yuen K.Y. Identification of slide coagulase positive, tube coagulase negative Staphylococcus aureus by 16S ribosomal RNA gene sequencing. Mol Pathol 2001, 54(4):244-247.
17. Clinical and Laboratory Standards Institute Performance standards for antimicrobial disk susceptibility tests-M02-A10 (includes M100-S20) 2010, Clinical and Laboratory Standards Institute, Wayne, PA.
18. Bill T.J., Ratliff C.R., Donovan A.M., Knox L.K., Morgan R.F., Rodeheaver G.T. Quantitative swab culture versus tissue biopsy: a comparison in chronic wounds. Ostomy Wound Manage 2001, 47(1):34-37.
19. Nelson E.A., O'Meara S., Craig D., Iglesias C., Golder S., Dalton J., et al. A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. Health Technol Assess 2006, 10(12). iii-iv, ix-x, 1-221.
20. Paterson D.L., Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005, 18(4):657-686.
21. Falagas M.E., Koletsi P.K., Bliziotis I.A. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006, 55(Pt 12):1619-1629.
22. Prompers L., Schaper N., Apelqvist J., Edmonds M., Jude E., Mauricio D., et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia 2008, 51(5):747-755.
23. Shakil S., Khan A.U. Infected foot ulcers in male and female diabetic patients: a clinico-bioinformative study. Ann Clin Microbiol Antimicrob 2010, 9:2.
24. Zubair M., Malik A., Ahmad J. Clinico-microbiological study and antimicrobial drug resistance profile of diabetic foot infections in North India. Foot (Edinb) 2011, 21(1):6-14.
25. Bowler P.G., Duerden B.I., Armstrong D.G. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 2001, 14(2):244-269.
26. Ng L.S., Kwang L.L., Yeow S.C., Tan T.Y. Anaerobic culture of diabetic foot infections: organisms and antimicrobial susceptibilities. Ann Acad Med Singapore 2008, 37(11):936-939.
27. Dow G. Bacterial swabs and the chronic wound: when, how, and what do they mean?. Ostomy Wound Manage 2003, 49(5A Suppl.):8-13.
28. Pellizzer G., Strazzabosco M., Presi S., Furlan F., Lora L., Benedetti P., et al. Deep tissue biopsy vs. superficial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infection. Diabet Med 2001, 18(10):822-827.
29. Slater R.A., Lazarovitch T., Boldur I., Ramot Y., Buchs A., Weiss M., et al. Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving bone. Diabet Med 2004, 21(7):705-709.
30. Ferech M., Coenen S., Malhotra-Kumar S., Dvorakova K., Hendrickx E., Suetens C., et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe. J Antimicrob Chemother 2006, 58(2):423-427.
31. Muller A., Mauny F., Talon D., Donnan P.T., Harbarth S., Bertrand X. Effect of individual- and group-level antibiotic exposure on MRSA isolation: a multilevel analysis. J Antimicrob Chemother 2006, 58(4):878-881.
32. Direcção Geral da Saúde Diabetic foot. National program for prevention and control of diabetes. Clinical Guidelines n°:05/PNPCD 2010.